Dihydroergotamine and its metabolite, 8′-hydroxy-dihydroergotamine, as 5-HT 1A receptor agonists in the rat brain

British Journal of Pharmacology

Volumn 139, Issue 2, 2003, Pages 424-434

  Hanoun, N ^a   Saurini, F ^a   Lanfumey, L ^a   Hamon, M ^a   Bourgoin, S ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

5 HT 1A receptors; 8 OH dihydroergotamine; 35S GTP S; Dihydroergotamine; Dorsal raphe nucleus; Firing rate; Hippocampus; Hyperpolarization; Migraine; Rat brain

Indexed keywords

8' HYDROXYDIHYDROERGOTAMINE; DIHYDROERGOTAMINE; ERGOTAMINE DERIVATIVE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG MECHANISM; ELECTROPHYSIOLOGY; HIPPOCAMPUS; HYPERPOLARIZATION; INTRACELLULAR RECORDING; MALE; MEMBRANE BINDING; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; BRAIN; DIHYDROERGOTAMINE; ELECTROPHYSIOLOGY; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; PYRAMIDAL CELLS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS;

EID: 0038605877     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705258     Document Type: Article

References (68)

1. AKERMAN, S., WILLIAMSON, D.J., HILL, R.G. & GOADSBY, P.J. (2001). The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur. J. Pharmacol., 424, 53-58.
2. ARANEDA, R. & ANDRADE R. (1991). 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability of rat association cortex. Neuroscience, 40, 399-412.
3. 1A receptors and intrinsic activity. Eur. J. Pharmacol., 386, 97-103.
4. 1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. J. Pharmacol. Exp. Ther., 163, 350-359.
5. BERDE, B. (1978) Pharmacology of ergot alkaloids in clinical use. Med. J. Aust., 2, 3-13.
6. BUZZI, M.G., CARTER, W.B., SHIMIZU, T., HEATH, H. III & MOSKOWITZ, M.A. (1991). Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology, 30, 1193-1200.
7. CHAPUT, Y., DE MONTIGNY, C. & BLIER, P. (1991). Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electro-physiologic study in the rat. Neuropsychopharmacology, 5, 219-229.
8. CHEN, X., ZHONG, D., XU, H., SCHUG, B. & BLUME, H. (2002). Sensitive and specific chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. J. Chromatogr. B. Biomed. Sci. Appl., 768, 267-275.
9. COHEN, Z., BONVENTO, G., LACOMBE, P. & HAMEL, E. (1996). Serotonin in the regulation of brain microcirculation. Prog. Neurobiol., 50, 335-362.
10. COLE, J.C. & RODGERS, R.J. (1994). Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology, 114, 288-296.
11. 1A receptors in the rat brain. Br. J. Pharmacol., 123, 449-462.
12. DE HOON, J.N.J.M., POPPE, K.A., THIJSSEN, H.H.W., STRUIJKER-BOUDIER, H.A.J. & VAN BORTEL, L.M.A.B. (2001). Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. Br. J. Clin. Pharmacol., 52, 45-51.
13. DIENER, H.C. & LIMMROTH, V. (2001). Advances in pharmacological treatment of migraine. Expert Opin. Investig. Drugs, 10, 1831-1845.
14. EDVINSSON, L., DEGUEURCE, A., DUVERGER, D., MACKENZIE, E.T. & SCATTON, B. (1983). Central serotonergic nerves project to the pial vessels of the brain. Nature, 306, 55-57.
15. 1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci., 12, 2299-2310.
16. 1A receptor modulation of anxiety in two ethological animal tests. J. Neurosci., 16, 4810-4815.
17. 1A receptor antagonist. Behav. Brain Res., 73, 337-353.
18. 3H]dopa in various regions of the brain. J. Neurochem., 13, 655-669.
19. GOADSBY, P.J., LIPTON, R.B. & FERRARI, M.D. (2002). Migraine-current understanding and treatment. N. Engl. J. Med., 346, 257-270.
20. GOLDSTEIN, J. (1992). Ergot pharmacology and alternative delivery systems for ergotamine derivatives. Neurology, 42(Suppl 2), 45-46.
21. 3H]PAT. Nature, 305, 140-142.
22. 1A receptors in rat brain membranes. Eur. J. Pharmacol. Mol. Pharmacol., 288, 173-186.
23. 1A receptor antagonists. Psychopharmacology, 144, 121-130.
24. 1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology, 27, 993-1001.
25. HADDJERI, N., SELETTI, B., GILBERT, F., DE MONTIGNY, C. & BLIER, P. (1998). Effect of ergotamine on serotonin-mediated responses in the rodent and human brain. Neuropsychopharmacology, 19, 365-380.
26. 1A autoreceptor interactions in the rat dorsal raphe nucleus: an in vitro electrophysiological study. Neuroscience, 41, 495-505.
27. 3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J. Neurochem., 44, 1685-1696.
28. HAMON, M. & BOURGOIN, S. (2000). Implications de la sérotonine et d'autres molécules neuroactives dans la physiopathogénie de la migraine. Hypothèses acuelles. Pathol. Biol., 48, 619-629.
29. 2B/2C de la sérotonine: des cibles potentielles pour le traitement prophylactique de la migraine Rev. Neurol. (Paris), 158, 2S190.
30. 1A receptors. Ann. Neurol., 19, 511-513.
31. HOSKIN, K.L., KAUBE, H. & GOADSBY, P.J. (1996). Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study, Brain, 119, 249-256.
32. 1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurones in the rat? J. Pharmacol. Exp. Ther., 272, 920-929.
33. LANTERI-MINET, M., ALCHAAR, H., BESSON, G., BILLE-TURC, F., BOUILLAT, J., BRUDON, F., DONNET, A., GALLETI, P., MAITRE, M., MOENE, Y., RAMBAUD, G., ROSTINI, C., VALANCE, J. & GASTAUT, J.L. (2000). Etude pharmaco-épidémiologique sur le traitement de fond de la migraine. Rev. Neurol. (Paris), 156, 1106-1112.
34. 1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. NeuroReport, 9, 2605-2608.
35. 1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology, 39, 110-122.
36. 1A agonist. J. Pharmacol. Exp. Ther., 279, 1035-1042.
37. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
38. MATHER, P.J., SILBERSTEIN, S.D., SCHULMAN, E.A. & HOPKINS, M.M. (1991). The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache, 31, 525-532.
39. McCARTHY, B.G. & PEROUTKA, S.J. (1989). Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache, 29, 420-422.
40. 1A agonists. Mol. Pharmacol., 37, 231-237.
41. MORENO, M.J., LOPEZ DE PABLO, A.L. & MARCO, E.J. (1994). Tryptophan hydroxylase activity in rat brain base arteries related to innervation originating from the dorsal raphe nucleus. Stroke, 25, 1046-1049.
42. NELSON, D.L., HERBET, A., BOURGOIN, S., GLOWINSKI, J. & HAMON, M. (1978). Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol. Pharmacol., 14, 983-995.
43. NEUMANN, M., DEMAREZ, J.P., HARMEY, J.L., LE BASTARD, B. & CAUQUIL, J. (1986). Prevention of migraine attacks through the use of dihydroergotamine. Int. J. Clin. Pharmacol. Res., 6, 11-13.
44. 1A receptors: potential implications for prophylactic and acute therapy. Naunyn-Schmiedeberg's Arch. Pharmacol., 355, 682-688.
45. NOZAKI, K., MOSKOWITZ, M.A. & BOCCALINI, P. (1992). CP-93, 129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br. J. Pharmacol., 106, 409-415.
46. PALMER, J.E., CHRONICLE, E.P., ROLAN, P. & MULLENERS, W.M. (2000). Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. Cephalalgia, 20, 525-532.
47. PASCUAL, J. & BERCIANO, J. (1991). An open trial of buspirone in migraine prophylaxis. Preliminary report. Clin. Neuropharmacol., 14, 245-250.
48. 1A receptor agonists in recombinant cell lines-modulation of apparent efficacy by G protein activation state. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 551-561.
49. PAXINOS, G. & WATSON, C. (1998). The Rat Brain In Stereotaxic Coordinates. 4th edn. London: Academic Press.
50. 1A receptor antagonist WAY 100635 on the inhibition of e.p.s.p, produced by 5-HT in the CA1 region of rat hippocampal slices. Br. J. Pharmacol., 124, 93-100.
51. RASKIN, N.H. (1991). Serotonin receptors and headache. N. Engl. J. Med., 325, 353-354.
52. ROQUEBERT, J. & GRENIE, B. (1986) Alpha2-adrenergic agonist and alpha 1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch. Int. Pharmacodyn. Ther., 284, 30-37.
53. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A., 90, 8547-8551.
54. 1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. Eur. J. Pharmacol., 220, 79-86.
55. 2B receptors: an early step in the generation of migraine headache? Eur. J. Neurosci., 8, 959-967.
56. SCOTT, A.K. (1992). Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin. Neuropharmacol., 15, 289-296.
57. SILBERSTEIN, S.D. (1997). The pharmacology of ergotamine and dihydroergotamine. Headache, 37, S15-S25.
58. 1A receptor-activated G-proteins in the rat brain. Brain Res. Bull., 44, 39-45.
59. 1A receptor-activated G-proteins in rat brain following chronic buspirone. Eur. J. Pharmacol., 389, 147-153.
60. SOMERVILLE, B.W. & HERMAN, W.M. (1978). Migraine prophylaxis with lisuride hydrogen maleate. A double-blind study of lisuride versus placebo. Headache. 18, 75-79.
61. 3H]lisuride labels free receptor and receptor coupled to G protein. J. Neurochem., 65, 1909-1916.
62. 7 receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol., 439, 1-11.
63. VANDERMAELEN, C.P. & AGHAJANIAN, G.K. (1983). Electrophysiological and pharmacological characterization of serotoninergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res., 289, 109-119.
64. 1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci., 6, 3474-3482.
65. WYSS, P.A., ROSENTHALER, J., NUESCH, E. & AELLIG, W.H. (1991). Pharmacokinetics investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur. J. Clin. Pharmacol., 41, 597-602.
66. YAMASHITA, S., OISHI, R. & GOMITA, Y. (1995). Anticonflict effects of acute and chronic treatments with buspirone and gepirone in rats. Pharmacol. Biochem. Behav., 50, 477-479.
67. 1A receptors negatively coupled to adenylate cyclase activity in rat hippocampal membranes. Mol. Pharmacol., 41, 1066-1072.
68. ZIFA E. & FILLION, G. (1992). 5-Hydroxytryptamine receptors. Pharmacol. Rev., 44, 401-458.